Bevacizumab and Trabectedin +/- Carboplatin in Advanced Ovarian Cancer

• ClinicalTrials.gov Identifier: NCT01735071
• Recruitment Status: Completed
• First Posted: November 28, 2012
• Last Update Posted: November 19, 2019
• Sponsor: Mario Negri Institute for Pharmacological Research
• Collaborators: PharmaMar; Hoffmann-La Roche
• Information provided by (Responsible Party): Mario Negri Institute for Pharmacological Research

Study Description

Brief Summary:

This study is aimed at assessing the efficacy and the safety of the combination of bevacizumab and trabectedin with or without carboplatin in adult women with epithelial ovarian cancer at first recurrence occurred 6-12 months after the end of the last (first or second) platinum-containing regimen. According to the Bryant and Day design the primary endpoints will be the proportion of progression-free patients at 6 months for the efficacy, and the proportion of patients with severe toxicity for the safety at the same time-point.

Condition or disease	Intervention/treatment	Phase
Ovarian Epithelial Cancer Recurrent	Drug: bevacizumab and trabectedin; Drug: bevacizumab, trabectedin and carboplatin	Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 71 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: This is a multicentre, randomized, non-comparative phase II study aimed at assessing efficacy and safety of two regimens according to a Bryant and Day two-stage design
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Multicenter, Randomized, Non-comparative, Phase II Trial on the Efficacy and Safety of the Combination of Bevacizumab and Trabectedin With or Without Carboplatin in Adult Women With Platinum Partially Sensitive Recurring Ovarian Cancer.
• Actual Study Start Date: July 2013
• Actual Primary Completion Date: March 18, 2018
• Actual Study Completion Date: March 18, 2018

Arms and Interventions

Arm	Intervention/treatment
Experimental: bevacizumab and trabectedin; Arm A: bevacizumab (15 mg/kg) given as 1 hour infusion will be followed by trabectedin (1.1 mg/sqm) 3 hour iv infusion; to be repeated every 21 days until progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients	Drug: bevacizumab and trabectedin; Arm A: bevacizumab (15 mg/kg) given as 1 hour infusion will be followed by trabectedin (1.1 mg/sqm) 3 hour iv infusion; to be repeated every 21 days until progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients; Other Names: Avastin; Yondelis
Experimental: bevacizumab, trabectedin and carboplatin; Arm B: cycle 1-6, bevacizumab given as 1 hour infusion will be followed by carboplatin area under curve 4 (AUC 4) and trabectedin 3 hour iv infusion. Cycle 7- end of treatment, bevacizumab given as 1 hour infusion will be followed by trabectedin 3 hour iv infusion. Patient enrolled in arm B will receive (cycle 1-6): trabectedin 0.8 mg/m2 ,carboplatin AUC 4 day 1 every 28 days and bevacizumab 10 mg/kg iv on day 1 and day 15. From cycle 7 to disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients will receive bevacizumab 15 mg/kg iv and trabectedin 1.1 mg/m2 day 1 every 21 days	Drug: bevacizumab, trabectedin and carboplatin; Arm B: cycle 1- 6, bevacizumab given as 1 hour infusion will be followed by carboplatin AUC 4 and trabectedin 3 hour iv infusion. Cycle 7- end of treatment, bevacizumab given as 1 hour infusion will be followed by trabectedin 3 hour iv infusion. Patient enrolled in arm B will receive (cycle 1-6): trabectedin 0.8 mg/m2 ,carboplatin AUC 4 day 1 every 28 days and bevacizumab 10 mg/kg iv on day 1 and day 15. From cycle 7 to disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients will receive bevacizumab 15 mg/kg iv and trabectedin 1.1 mg/m2 day 1 every 21 days; Other Names: Avastin; Yondelis; Carboplatin

Outcome Measures

Primary Outcome Measures :

1. Progression Free Survival at 6 months (PFS-6) [ Time Frame: from randomization up to 6 months ]
   The PFS-6, defined as the percentage of patients who are alive and progression free at 6 months after the randomization.
2. Proportion of patients with severe toxicity within 6 months from randomization. [ Time Frame: from randomization up to 6 months ]

   The following conditions will be considered as severe toxicity:

   • absolute neutrophil count (ANC) < 0.5x109/L lasting > 7 days and/or with fever
   • platelets < 25x109/L
   • any other grade 3-4 (evaluated by the National Cancer Institute-Common Terminology Criteria for Adverse Events [NCI-CTCAE] version 4.0) non-hematological toxicities except for reversible nausea/vomiting, diarrhea, hypersensitivity reactions, and alanine aminotransferase (ALT) or aspartate aminotransferase (AST) elevation reversible to grade 1 by day 28
   • any toxicity causing a delay of >14 days in the following cycle

Secondary Outcome Measures :

1. Progression Free Survival (PFS) [ Time Frame: from randomization up to 30 months ]
   Defined for each patient as the time from the date of randomization to the date of first progression, second primary malignancy or death for any cause, whichever comes first. Subjects not progressed or died at the time of the analysis will be censored at the last disease assessment date.
2. Overall survival at 12 months (OS-12) [ Time Frame: one year ]
   Defined as the percentage of patients who are alive at 12 months after the randomization.
3. Clinical Benefit (CB) [ Time Frame: from randomization up to 30 months ]
   clinical benefit, defined as the percentage of patients who are judged by the Investigators to have a complete response (CR), or partial response (PR) or stable disease (SD) according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria, version 1.1 after 12 weeks from the date of randomization.
4. Incidence of Adverse Events (AEs) [ Time Frame: from randomization up to 30 months ]
   Incidence of AEs, according to NCI-CTCAE, version 4.0
5. Maximum toxicity grade [ Time Frame: from randomization up to 30 months ]
   Maximum toxicity grade experienced by each patient for each specific toxicity
6. Percentage of patients experiencing grade 3-4 toxicity for each specific toxicity [ Time Frame: from randomization up to 30 months ]
   Percentage of patients experiencing grade 3-4 toxicity for each specific toxicity during the study
7. Patients with at least a Serious Adverse Drug Reaction (SADR) [ Time Frame: from randomization up to 30 months ]
   Patients with at least a SADR during the study
8. Patients with at least a Suspect Unexpected Serious Adverse Reaction (SUSAR). [ Time Frame: from randomization up to 30 months ]
   Patients with at least a suspect unexpected serious adverse reaction during the study
9. Percentage of patients with dose and/or time modifications [ Time Frame: from randomization up to 30 months ]
   Percentage of patients with dose and/or time modifications of the study drugs
10. Percentage of premature withdrawals [ Time Frame: from randomization up to 30 months ]
    Percentage of premature withdrawals of the enrolled patients
11. Patients with at least a Serious Adverse Event (SAE) [ Time Frame: from randomization up to 30 months ]
    Patients with at least a SAE during the study
12. Nature of AEs [ Time Frame: from randomization up to 30 months ]
    Nature of AEs, according to NCI-CTCAE, version 4.0
13. Severity of AEs [ Time Frame: from randomization up to 30 months ]
    Severity of AEs, according to NCI-CTCAE, version 4.0
14. Seriousness of AEs [ Time Frame: from randomization up to 30 months ]
    Seriousness of AEs according to NCI-CTCAE, version 4.0

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Age≥18years
• Eastern Cooperative Oncology Group (ECOG)- performance status 0-2
• Cytological/histological diagnosis of epithelial ovarian cancer
• Progression free interval between 6-12 months (calculated from the first day of the last cycle of the previous last platinum-based chemotherapy until the date of progression confirmation through radiologic imaging)
• One or two previous platinum-based chemotherapy lines
• Measurable disease according to RECIST version 1.1
• Life expectancy ≥ 12 weeks
• Patients must be able to receive dexamethasone or its equivalent, as a premedication for trabectedin
• Written informed consents given before the enrolment according to International Conference on Harmonization/ Good Clinical Practice (ICH/GCP).

Exclusion Criteria:

• Prior treatment with trabectedin
• Prior progression while on therapy containing bevacizumab or other vascular endothelial growth factor (VEGF) pathway-target therapy
• Pre-existing grade > 1 sensitive/motor neurologic disorder
• Current or recent (within 30 days of first study dosing) treatment with another investigational drug
• Surgery (including open biopsy) within 4 weeks prior to the first planned dose of bevacizumab
• Current or recent (within 10 days prior to the first study drug dose) use of full-dose oral or parenteral anticoagulant or thrombolytic agent for therapeutic purposes (except for line patency, in which case international normalized ratio (INR) must be maintained below 1.5). Post operative prophylaxis with low molecular weight heparin sc is allowed
• Inadequate bone marrow function: absolute neutrophil count (ANC): <1.5 x 109/l, or platelet count <100 x 109/l or haemoglobin <9 g/dl. Patients may be transfused to maintain haemoglobin values ≥9 g/dl
• Inadequate coagulation parameters: activated partial thromboplastin time (APTT) >1.5 x upper limit of normal (ULN) or INR >1.5
• Inadequate liver function, defined as: serum (total) bilirubin > ULN for the institution AST/serum glutamic-oxaloacetic transaminase (SGOT) or ALT/ serum glutamic-pyruvic transaminase (SGPT) >2.5 x ULN
• Inadequate renal function: serum creatinine >1.5 mg/dL or >132 micromol/L and urine dipstick for proteinuria > or = 2+ and >1g of protein in their 24-hour urine collection
• History or evidence of brain metastases or spinal cord compression
• Pregnant, breastfeeding women and women of child bearing potential, who do not agree to use a medically acceptable method of contraception through the treatment period and for 6 months after discontinuation of treatment
• History or evidence of thrombotic or hemorrhagic disorders; including cerebrovascular accident, stroke or transient ischemic attack or sub-arachnoid haemorrhage within 6 months prior to the first study treatment
• Uncontrolled hypertension (sustained systolic >150 mmHg and/or diastolic >100 mmHg despite antihypertensive therapy) or clinically significant (i.e. active) cardiovascular disease, including: myocardial infarction or unstable angina within 6 months prior to the first study treatment, New York Heart Association grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication
• History of bowel obstruction, including subocclusive disease, related to the underlying disease and history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess. Evidence of recto-sigmoid involvement by pelvic examination or bowel involvement on CT scan or clinical symptoms of bowel obstruction
• Non-healing wound, ulcer or bone fracture
• hepatitis C virus (HCV) positivity
• Other malignancy within the last 5 years, except for adequately treated carcinoma in situ of the cervix or squamous carcinoma of the skin, or adequately controlled limited basal cell skin cancer.

Contacts and Locations

Locations

Italy

Azienda Ospedaliera Spedali Civili di Brescia

Brescia, Italy

AO Fatebenefratelli e Oftalmico

Milano, Italy

Istituto Europeo di Oncologia

Milan, Italy

Azienda Ospedaliera S. Gerardo

Monza, Italy

Istituto Oncologico Veneto

Padova, Italy

Policlinico Universitario Agostino Gemelli di Roma

Roma, Italy

Mauriziano Hospital

Torino, Italy

Sponsors and Collaborators

Mario Negri Institute for Pharmacological Research

PharmaMar

Hoffmann-La Roche

Investigators

• Principal Investigator: Nicoletta Colombo, Medical D; IRCCS Istituto Europeo di Oncologia di Milano

More Information

Publications of Results:

Colombo N, Zaccarelli E, Baldoni A, Frezzini S, Scambia G, Palluzzi E, Tognon G, Lissoni AA, Rubino D, Ferrero A, Farina G, Negri E, Pesenti Gritti A, Galli F, Biagioli E, Rulli E, Poli D, Gerardi C, Torri V, Fossati R, D'Incalci M. Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer. Br J Cancer. 2019 Oct;121(9):744-750. doi: 10.1038/s41416-019-0584-5. Epub 2019 Sep 20.

• Responsible Party: Mario Negri Institute for Pharmacological Research
• ClinicalTrials.gov Identifier: NCT01735071
• Other Study ID Numbers: IRFMN-OVA-6152
• First Posted: November 28, 2012
• Last Update Posted: November 19, 2019
• Last Verified: November 2019

Keywords provided by Mario Negri Institute for Pharmacological Research:

ovarian cancer; bevacizumab; trabectedin; carboplatin; randomized trial; phase II

Additional relevant MeSH terms:

Ovarian Neoplasms; Carcinoma, Ovarian Epithelial; Endocrine Gland Neoplasms; Neoplasms by Site; Neoplasms; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Neoplasms, Female; Urogenital Neoplasms; Genital Diseases; Endocrine System Diseases; Gonadal Disorders; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Bevacizumab; Carboplatin; Trabectedin; Antineoplastic Agents, Immunological; Antineoplastic Agents; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Growth Substances; Physiological Effects of Drugs; Growth Inhibitors; Antineoplastic Agents, Alkylating